Login
Super Investors PGIM Jennison Health Sciences Fund

PGIM Jennison Health Sciences Fund

Prudential Sector Funds, Inc. · net assets $1.5B · 55 holdings as of August 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.

Asset mix

EC: 90.1% · STIV: 9.9%

Financial position

Total assets
$1.55B
Total liabilities
$47.3M
Net assets
$1.5B
Assets attributable to miscellaneous securities
$0
Assets invested in controlled foreign corporations
$0
Borrowings payable within one year
$0
Payable to controlled companies within one year
$0
Payable to other affiliates within one year
$0
Other liabilities payable within one year
$0
Borrowings payable after one year
$0
Payable to controlled companies after one year
$0
Payable to other affiliates after one year
$0
Other liabilities payable after one year
$0
Payables for delayed-delivery investments
$0
Payables for standby commitments
$0
Liquidation preference of outstanding preferred stock
$0
Cash not reported in Parts C or D
$0

Monthly flows and gains

Month 1 Month 2 Month 3
Sales $11M $12M $16.3M
Reinvestment $0 $0 $0
Redemptions $23.8M $25M $31.2M
Net realized gain (non-derivative) $9.35M $24.4M $1.31M
Net unrealized appreciation (non-derivative) $102M -$40.2M $53.9M

The three months of the reporting period, as filed; month 3 ends August 31, 2026.

Filing details

Registrant
Prudential Sector Funds, Inc.
Registrant CIK
352665
Registrant LEI
549300IPCXL88G4QUI19
Series
PGIM Jennison Health Sciences Fund
Series ID
S000004380
Series LEI
S41LI155RNUZ4KJ9CN75
SEC file number
811-03175
Address
655 Broad Street, Newark, US-NJ, 07102-4077, US
Phone
1-800-225-1852
Form
NPORT-P
Filed
October 29, 2026
Report period ends
November 30, 2026
Report month ends
August 31, 2026
Accession number
000094040026041747
Holding Value % of net assets
Eli Lilly & Company EC $252M 16.84%
Prudential Government Money Market Fund Inc. STIV $107M 7.14%
Merck & Company Inc EC $105M 6.99%
Unitedhealth Group Inc EC $83.4M 5.57%
Thermo Fisher Scientific Inc EC $72.2M 4.82%
Vertex Pharmaceuticals Inc EC $62M 4.14%
Argenx Se EC $52.4M 3.50%
Danaher Corp EC $49.9M 3.33%
Prudential Investment Portfolios 2 STIV $45.9M 3.06%
Cvs Health Corp EC $41.5M 2.77%
Insmed Inc EC $36.1M 2.41%
Roivant Sciences Ltd EC $35.4M 2.36%
Beone Medicines Ltd EC $34.3M 2.29%
Palvella Therapeutics Inc EC $29.3M 1.96%
Kymera Therapeutics Inc EC $25.6M 1.71%
Edwards Lifesciences Corp EC $24.3M 1.62%
Elanco Animal Health Inc EC $22.2M 1.48%
Vaxcyte Inc EC $21.8M 1.46%
Agilent Technologies Inc EC $21.3M 1.42%
Align Technology Inc EC $21.1M 1.41%
Dianthus Therapeutics Inc EC $20.1M 1.34%
Revolution Medicines Inc EC $19.3M 1.29%
Tarsus Pharmaceuticals Inc EC $18.4M 1.23%
Elevance Health Inc EC $17.9M 1.20%
Intuitive Surgical Inc EC $17.8M 1.19%
Scholar Rock Holding Corp EC $17.5M 1.17%
Erasca Inc EC $16.7M 1.12%
Protagonist Therapeutics Inc EC $16.4M 1.10%
Uniqure Nv EC $16.4M 1.10%
Disc Medicine Inc EC $15.6M 1.04%
Cabaletta Bio Inc EC $15.4M 1.03%
Tandem Diabetes Care Inc EC $15M 1.00%
Newamsterdam Pharma Company Nv EC $13.5M 0.90%
Lonza Group Ag EC $13.4M 0.90%
Apnimed Inc EC $12.8M 0.86%
Veradermics Inc EC $12.6M 0.84%
Immunovant Inc EC $11.3M 0.76%
Celcuity Inc EC $11.1M 0.74%
Avalyn Pharma Inc EC $11.1M 0.74%
Lb Pharmaceuticals Inc EC $10.9M 0.73%
Seaport Therapeutics Inc EC $10.4M 0.69%
Arcutis Biotherapeutics Inc EC $9.38M 0.63%
Abivax Sa EC $9.34M 0.62%
Kardigan Inc EC $8.26M 0.55%
Xenon Pharmaceuticals Inc EC $7.87M 0.53%
Mineralys Therapeutics Inc EC $7.41M 0.49%
Spyre Therapeutics Inc EC $7.34M 0.49%
Oruka Therapeutics Inc EC $7.08M 0.47%
Sionna Therapeutics Inc EC $5.63M 0.38%
Enliven Therapeutics Inc EC $5.58M 0.37%
Crescent Biopharma Inc EC $5.17M 0.35%
Neurogene Inc EC $4.57M 0.31%
Damora Therapeutics Inc EC $4.31M 0.29%
Tyra Biosciences Inc EC $3.79M 0.25%
Cabaletta Bio Inc Warrant EC $1.3M 0.09%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support